secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0001213900-24-023584
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Oramed appoints Yehuda Reznick as director and audit committee chair effective April 1, 2024
--------------------------------------------------------------------------------

- Yehuda Reznick appointed to fill existing board vacancy; also audit committee chair and designated financial expert.
- Reznick, 76, was an audit partner at Kesselman & Kesselman (PwC affiliate) from 1999 to 2014.
- Compensation same as other non-executive directors; standard indemnification agreement expected.
- Currently serves on board of Oravax Medical Inc., an affiliate of Oramed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390024023584/0001213900-24-023584-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390024023584/ea0201979-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-023584

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer